The purpose of this study was to see if Bempedoic acid which is an ATP citrate Lysae Inhibitor can be used to reduce cardio-vascular outcomes in patients who are statin-intolerant. Patients who are statin intolerant report adverse musculoskeletal effects and withdrawal from statin treatment is associated with an increased risk of cardiovascular event. Patients between the ages of 18-85 years were eligible for this study if they met either of the two criteria which was if they had a previous cardiovascular event or clinical features that put them at high risk of cardiovascular event. 13,970 patients underwent randomization; 6,992 were assigned to the bempedoic acid group and 6,978 to the placebo group. The patients who were assigned Bempedoic acid group were given 180 mg daily to take. The median Cholesterol level was 139.0 per deciliter and after 6 months the reduction in the level was greater with bempedoic acid than with placebo by 29.2 mg per deciliter, and bempedoic acid reduced the highsensitivity CRP level as compared with placebo. The researchers found that among statin-intolerant patients’ treatment with bempedoic acid was associated with lower risk of cardiovascular events such as myocardial infarction, nonfatal stroke and coronary revascularization